omega-3-carboxylic acids · Astrazeneca · NDA 205060
Epanova
Earliest generic entry, as listed
4 Jan 2033
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10117844, US 9050308, US 9050309.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10117844 | use U-2447 · sets the listed date | 4 Jan 2033 |
| US 9050308 | use U-1511 · sets the listed date | 4 Jan 2033 |
| US 9050309 | drug substance · sets the listed date | 4 Jan 2033 |
| US 7960370 | drug product | 20 Dec 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 205060 · 001 · RLD · discontinued | capsule, oral | 1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS | 4 Jan 2033 |